# Molecular Cancer Therapeutics

## December 2010 • Volume 9 • Number 12

### Highlights of This Issue

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3103</td>
</tr>
</tbody>
</table>

### SPOTLIGHT ON MOLECULAR PROFILING

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3105</td>
</tr>
</tbody>
</table>

**Genome-Wide mRNA and microRNA Profiling of the NCI 60 Cell-Line Screen and Comparison of FdUMP[10] with Fluorouracil, Fluoruridine, and Topoisomerase 1 Poisons**  
William H. Gmeiner, William C. Reinhold, and Yves Pommier  
3164

### REVIEWS

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3115</td>
</tr>
</tbody>
</table>

**Breaking through a Plateau in Renal Cell Carcinoma Therapeutics: Development and Incorporation of Biomarkers**  
Sumanta Kumar Pal, Marcin Kortylewski, Hua Yu, and Robert A. Figlin  
3175

**Resistance May Not Be Futile: microRNA Biomarkers for Chemoresistance and Potential Therapeutics**  
Kristi E. Allen and Glen J. Weiss  
3186

**Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations**  
Asfar S. Azmi, Zhiwei Wang, Philip A. Philip, Ramzi M. Mohammad, and Fazlul H. Sarkar  
3200

### THERAPEUTIC DISCOVERY

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3145</td>
</tr>
</tbody>
</table>

**The Quassinoid Derivative NBT-272 Targets Both the AKT and ERK Signaling Pathways in Embryonal Tumors**  
Deborah Castelletti, Giulio Fiaschetti, Valeria Di Dato, Urs Ziegler, Candy Kumps, Katieen De Preter, Massimo Zollo, Frank Speleman, Tarek Shalaby, Daniela De Martino, Thorsten Berg, Angelika Eggert, Alexandre Arcaro, and Michael A. Grotzer  
3210

**Modulation of 4E-BP1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis**  
Chad A. Dumstorf, Bruce W. Konicek, Ann M. McNulty, Stephen H. Parsons, Luc Furic, Nahum Sonenberg, and Jeremy R. Graff  

**Antagonism of Cytotoxic Chemotherapy in Neuroblastoma Cell Lines by 13-cis-Retinoic Acid Is Mediated by the Antiapoptotic Bcl-2 Family Proteins**  
Michael D. Hadjidaniel and C. Patrick Reynolds  

**Monensin Is a Potent Inducer of Oxidative Stress and Inhibitor of Androgen Signaling Leading to Apoptosis in Prostate Cancer Cells**  
Kirsi Ketola, Paula Vainio, Vidal Fey, Olli Kallioniemi, and Kristiina Iljin  

**Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer**  

**Combined Inhibition of Notch Signaling and Bcl-2/Bcl-xL Results in Synergistic Antimyeloma Effect**  
Ming Li, Feng Chen, Nicholas Clifton, Daniel M. Sullivan, William S. Dalton, Dmitry I. Gabrielovich, and Yulia Nefedova  

**The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss**  
Jitesh Pratap, Jacqueline Akech, John J. Wixted, Gabriela Szabo, Sadj Hussain, Meghan E. McGee-Lawrence, Xiaodong Li, Krystin Bedard, Robinder J. Dhillon, Andre J. van Wijnen, Janet L. Stein, Gary S. Stein, Jennifer J. Westendorf, and Jane B. Lian  

---

**Contents**

Integrating Targets, Technologies, and Treatments  
www.aacrjournals.org

Downloaded from mct.aacrjournals.org on June 15, 2017. © 2010 American Association for Cancer Research.
### PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-\(\gamma\) ACTIVATION INHIBITS TUMOR METASTASIS BY ANTAGONIZING SMAD3-MEDIATED EPITHELIAL-MESENCHYMAL TRANSITION

Ajaya Kumar Reka, Himabindu Kurapati, Venkata R. Narala, Guido Bommer, Jun Chen, Theodore J. Standiford, and Venkateshwar G. Keshamouni

### COMBINED TREATMENT WITH SILIBININ AND EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS OVERCOMES DRUG RESISTANCE CAUSED BY T790M MUTATION

Jin Kyung Rho, Yun Jung Choi, Byung-Suk Jeon, Su Jin Choi, Gi Jeong Cheon, Sang-Keun Woo, Hye-Ryoun Kim, Cheol Hyeon Kim, Chang-Min Choi, and Jae Cheol Lee

### ANTIANGIOGENIC ACTIVITY OF A NEUTRALIZING HUMAN SINGLE-CHAIN ANTIBODY FRAGMENT AGAINST FIBROBLAST GROWTH FACTOR RECEPTOR 1

Roberto Ronca, Patrizia Benzoni, Daria Leali, Chiara Urbiniati, Mirella Belleri, Michela Corsini, Patrizia Alessi, Daniela Coltrini, Stefano Calza, Marco Presta, and Patrizia Dell’Era

### MS-275 SENSITIZES TRAIL-RESISTANT BREAST CANCER CELLS, INHIBITS ANGIOGENESIS AND METASTASIS, AND REVERSES EPITHELIAL-MESENCHYMAL TRANSITION IN VIVO

Rakesh K. Srivastava, Razelle Kurzrock, and Sharmila Shankar

### PRECLINICAL DEVELOPMENT

#### DETECTION OF TUMOR RESPONSE TO A VASCULAR DISRUPTING AGENT BY HYPERPOLARIZED \(^{13}\)C MAGNETIC RESONANCE SPECTROSCOPY

Sarah E. Bohndiek, Mikko I. Kettunen, De-en Hu, Timothy H. Witney, Brett W.C. Kennedy, Ferdia A. Gallagher, and Kevin M. Brindle

#### COMBINATION OF VORINOstat AND FLAVOPIRIDOL IS SELECTIVELY CYTOTOXIC TO MULTIDRUG-RESISTANT NEUROBLASTOMA CELL LINES WITH MUTANT TP53

Jen-Ming Huang, Michael A. Sheard, Lingyun Ji, Richard Sposto, and Nino Keshelava

#### INHIBITION OF CONSTITUTIVE ACTIVATION OF STAT3 BY CURCURBITACIN-1 (JSI-124) SENSITIZES HUMAN B-LEUKEMIA CELLS TO APOPTOSIS

Ganchimeg Ishidorj, James B. Johnston, and Spencer B. Gibson

#### CYTOCHROME P450 1B1 GENE POLYMORPHISMS AS PREDICTORS OF ANTICANCER DRUG ACTIVITY: STUDIES WITH IN VITRO MODELS

Audrey Laroche-Clary, Valérie Le Morvan, Takao Yamori, and Jacques Robert

#### Rb–Raf-1 INTERACTION DISRUPTOR RRD-251 INDUCES APOPTOSIS IN METASTATIC MELANOMA CELLS AND SYNERGIZES WITH DACARBAZINE

Sandeep Singh, Rebecca Davis, Vignesh Alamantha, Roberta Pireddu, Daniel Pernazza, Said Sebti, Nicholas Lawrence, and Srikumar Chellapappan

#### CYCLIN G–ASSOCIATED KINASE IS NECESSARY FOR OSTEOSARCOMA CELL PROLIFERATION AND RECEPTOR TRAFFICKING

Michiro Susa, Edwin Choy, Xianzhe Liu, Joseph Schwab, Francis J. Hornick, Henry Mankin, and Zhenfeng Duan

#### IDENTIFICATION OF PREDICTIVE MARKERS OF RESPONSE TO THE MEKfs1/2 INHIBITOR SULMETINIB (AZD6244) IN K-ras–MUTATED COLORECTAL CANCER

John J. Tentler, Sujatha Nallapareddy, Aik Choon Tan, Anna Spreafo, Todd M. Pitts, M. Pia Morelli, Heather M. Selby, Maria I. Kachaeva, Sara A. Flanigan, Gillian N. Kulikowski, Stephen Leong, John J. Arcaroli, Wells A. Messersmith, and S. Gail Eckhardt
Contrasting Effects of Nutlin-3 on TRAIL- and Docetaxel-Induced Apoptosis Due to Uregulation of TRAIL-R2 and Mcl-1 in Human Melanoma Cells
Hsin-Yi Tseng, Chen Chen Jiang, Amanda Croft, Kwang Hong Tay, Rick Francis Thorne, Fan Yang, Hao Liu, Peter Hersey, and Xu Dong Zhang

Nakiterpiosin Targets Tubulin and Triggers Mitotic Catastrophe in Human Cancer Cells
Jen-Hsuan Wei and Joachim Seemann

AZ960, a Novel Jak2 Inhibitor, Induces Growth Arrest and Apoptosis in Adult T-Cell Leukemia Cells
Jing Yang, Takayuki Ikezoe, Chie Nishioka, Mutsuo Furihata, and Akihito Yokoyama

Specific Alterations of MicroRNA Transcriptome and Global Network Structure in Colorectal Carcinoma after Cetuximab Treatment
Marco Ragusa, Alessandra Majorana, Luisa Statello, Marco Maugeri, Loredana Salito, Davide Barbagallo, Maria Rosa Guglielmino, Laura R. Duro, Rosario Angelica, Rosario Calabiano, Antonio Biondi, Maria Di Vita, Giuseppe Privitera, Marina Scalia, Alessandro Cappellani, Enrico Vasquez, Salvatore Lanzafame, Francesco Basile, Cinzia Di Pietro, and Michele Purrello

Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer
Apostolia-Maria Tsimberidou, Wallace Akerley, Matthias C. Schabel, David S. Hong, Cynthia Uehara, Anil Chhabra, Terri Warren, Gary G. Mather, Brent A. Evans, Deane P. Woodland, Edward A. Swabb, and Razelle Kurzrock

Acknowledgment to Reviewers

ABOUT THE COVER
Aldehyde dehydrogenase-1A1 (ALDH1A1) is heterogeneously expressed in multiple tumors. Cells with ALDH1A1 activity have been shown to have increased tumorigenicity, differentiation capacity, and chemoresistance. To confirm that the spotty heterogeneous expression of ALDH1A1 was not being visualized in tumor-infiltrating macrophages, frozen patient samples were subjected to dual immunohistochemistry against ALDH1A1 (DAB/brown) and CD68 (a pan-macrophage marker, Ferangi Blue), where distinct populations are noted. Landen and colleagues show that increased ALDH1A1 expression was associated with poor survival and is a viable target for therapy in preclinical models of ovarian cancer. For details, see article by Landen and colleagues on page 3186.